The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use
about
The 1.65 Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognitionStructurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines.Safety and efficacy of the multitargeted receptor kinase inhibitor pazopanib in the treatment of corneal neovascularization.Treating patients with metastatic renal carcinoma: an escape from Phase III.Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor.Evaluating surrogacy metrics and investigating approval decisions of progression-free survival (PFS) in metastatic renal cell cancer: a systematic review.Overview of fundamental study of pazopanib in cancer.Pharmacokinetic interaction between pazopanib and cisplatin regimen.Efficacy of targeted therapy for advanced renal cell carcinoma: a systematic review and meta-analysis of randomized controlled trials.Synthesis of Novel Pyrimidin-4-One Bearing Piperazine Ring-Based Amides as Glycogen Synthase Kinase-3β Inhibitors with Antidepressant Activity.
P2860
Q27698320-54CDD0E4-6273-4479-8D80-83C66234A276Q31085777-90F287DE-0516-447D-91B2-779879E8FC5DQ36571709-232FBB57-F1AA-40D6-BFAF-5FB661642560Q38030592-5BCA271B-CA5C-43DC-A58D-31FDD04D7442Q38110320-15E7DE8B-27A7-4324-82CC-31B80F824C6EQ38233353-C95E0A3B-38E1-4020-9493-C49FDE55AC4DQ38696525-FBACDA6B-AB33-4BE9-A8F7-14FAB4EC842FQ40094748-94A2345F-A9EA-437E-AF51-C163FF2C7FD1Q47358265-EEAE526A-E29A-41EA-A415-FEBFEB7AA7C5Q55033148-C04815F6-4574-41B7-B2A7-34B0557A4A4D
P2860
The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The European Medicines Agency ...... dicinal Products for Human Use
@ast
The European Medicines Agency ...... dicinal Products for Human Use
@en
The European Medicines Agency ...... dicinal Products for Human Use
@nl
type
label
The European Medicines Agency ...... dicinal Products for Human Use
@ast
The European Medicines Agency ...... dicinal Products for Human Use
@en
The European Medicines Agency ...... dicinal Products for Human Use
@nl
prefLabel
The European Medicines Agency ...... dicinal Products for Human Use
@ast
The European Medicines Agency ...... dicinal Products for Human Use
@en
The European Medicines Agency ...... dicinal Products for Human Use
@nl
P2093
P1476
The European Medicines Agency ...... dicinal Products for Human Use
@en
P2093
B. van Zwieten-Boot
F. Pignatti
G. J. A. ten Bosch
J. Borregaard
J. Ersboll
J. H. M. Schellens
P304
P356
10.1158/1078-0432.CCR-11-1734
P407
P577
2011-11-01T00:00:00Z